DaVita (DVA) concentration risks

The company's disclosed concentration profile is dominated by its payor mix, with government-based programs constituting the largest disclosed share of revenue. The filing identifies total government-based programs as the leading payor category, a large-share exposure by disclosed size with a structural character — the company's business of providing kidney dialysis services places the majority of its patient population in Medicare and Medicaid programs by the nature of end-stage renal disease demographics. Within that, Medicare and Medicare Advantage plans are explicitly noted as the largest component, also a large-share structural exposure. Layered against these structural government dependencies is a moderate-share commercial payor relationship. The filing notes that payments from commercial payors generate nearly all of the company's profits and all non-hospital dialysis profits. This creates a meaningful tension: most patients are covered by government programs, but the economics of the business are disproportionately driven by the smaller commercial payor segment. A deterioration in commercial payor rates, a shift in patient mix toward government-only coverage, or adverse rate adjustments in Medicare reimbursement could compress margins materially. Because the source quotes for government-based program percentages appear in pipe-delimited table format, those figures are described qualitatively. On balance, the primary watchpoints are Medicare reimbursement rate policy, commercial payor contract terms, and any regulatory changes that affect the profitability differential between government and commercial coverage in dialysis services.

For the engine’s reasoning on DVA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.